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Abstract 
Prostate Cancer (PCa) is the most common cancer and the second leading cause of 
cancer-related death in males. When PCa acquires castration resistance, incurable 
metastases, primarily in the bone, occur. The aim of this study is to test the applica-
bility of targeting MCAM (CD146) with a monoclonal antibody for the treatment of lytic 
PCa bone metastasis. We evaluated the effect of targeting MCAM using in vivo pre-
clinical bone metastasis models and an in vitro bone niche co-culture system. We 
utilized FACS, cell proliferation assays, and gene expression profiling to study the 
phenotype and function of MCAM knockdown in vitro and in vivo. To demonstrate the 
impact of MCAM targeting and therapeutic applicability, we employed an anti-MCAM 
monoclonal antibody in vivo. MCAM is elevated in PCa metastases resistant to an-
drogen-ablation. Treatment with Dihydrotestosterone showed MCAM upregulation 
upon castration. We investigated the function of MCAM in a direct co-culture model of 
human PCa cells with human osteoblasts and found that there is reduced influence of 
human osteoblasts on human PCa cells in which MCAM has been knocked down. 
Furthermore, we observed strongly reduced formation of osteolytic lesions upon 
bone-inoculation of MCAM-depleted human PCa cells in animal model of PCa bone 
metastasis. This phenotype is supported by RNA Sequencing analysis. Importantly, 
in vivo administration of an anti-MCAM human monoclonal antibody reduced tumor 
growth and lytic lesions. These results highlight the functional role for MCAM in the 
development of lytic-bone metastasis and suggest that MCAM is a potential thera-
peutic target in PCa bone metastasis. 
 
Implications: 
This study highlights the functional application of an anti-MCAM monoclonal antibody 
to target prostate cancer bone metastasis.   
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Introduction 
Prostate cancer (PCa) is the most common cancer and the second leading cause 
cancer-related death in men (1). Current treatments such as radiation therapy and 
androgen deprivation therapies (ADTs) are effective when the cancer is still confined 
at the primary site (2). However, after the tumor progresses and acquires castration 
resistance, the development of incurable metastases is almost inevitable(3).  
PCa metastases occur at specific sites with one of the most common locations being 
the bone, where the occurrence of both lytic- and blastic-lesions has been 
documented (4). Previous studies demonstrated that PCa cells colonize the bone 
microenvironment within the so called “hematopoietic stem cell (HSC) niche” (3,5). 
PCa metastasis initiating cells (MICs) compete with the bone marrow (BM) cells for 
the occupancy of this microenvironment and induce an ectopic epithelial tissue-of-
origin niche, referred as a “developmental prostate niche” (6).  
Melanoma Cell Adhesion Molecule (MCAM/CD146) is a cell-surface glycoprotein 
composed of five immunoglobulin-like domains, one transmembrane region, and a 
short cytoplasmic tail, which interacts with the cytoskeleton (7). Growing evidence 
supports the notion that high MCAM expression in a variety of carcinomas positively 
correlates with poor prognosis in prostate cancer (8), melanoma (9), pulmonary 
adenocarcinomas (10), epithelial ovarian cancer (11), and breast cancer (12). 
Overexpression of MCAM has been shown to increase tumorigenicity of human 
osteoblastic PCa cells (LNCaP) in vivo (13). Additionally, MCAM was shown to 
induce epithelial-to-mesenchymal transition (EMT) in breast cancer, a process 
thought to be involved in the initiation of metastasis (14). 
Upon transplantation, MCAM-expressing subendothelial cells in human BM stroma 
are capable of recapitulating hematopoiesis in heterotopic sites (15). This established 
the notion that MCAM-positive subendothelial cells are relevant to hematopoiesis and 
play key roles in the maintenance of the HSC niche. Previously, we identified a gene 
signature for the effect that PCa cells exert on the bone stroma in a bone metastasis 
xenograft mouse model (6). This included MCAM as a potential mediator of the 
metastatic colonization and growth of PCa cells in the bone in lytic- and blastic-bone 
metastases (6). The extracellular domain of MCAM can engage in heterophilic 
binding with various ligands (e.g. Laminin-411). It has also been proposed that 
homophilic binding with other MCAM molecules (16) might be occurring, suggesting 
that targeting MCAM on either tumor cells or stromal cells might have a functional 
effect on PCa cell behavior. 
In this study, we show that administration of an anti-MCAM monoclonal antibody 
reduces intra-osseous growth and lytic lesions in preclinical models of PCa bone 
metastasis. We provide evidence that MCAM is strongly increased in androgen-
ablation resistant metastases derived from PCa and show that MCAM knockdown 
reduces PCa cell proliferation and osteoblast-mediated induction of ALDH activity. 
Taken together, these findings suggest that MCAM supports the metastatic lytic-
phenotype in human PCa cells and represents a possible therapeutic target in PCa 
patients with bone metastasis. 
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Materials and Methods 
 
Cell lines and culture conditions 
All the human cell lines employed in this study have been authenticated using highly-
polymorphic short tandem repeat loci (STRs). Additionally, all the human cell lines 
have been previously validated in vitro and in vivo (17-19). PC-3M-Pro4 were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, GibcoBRL, Waltham, USA) 
containing 4.5 g glucose/l supplemented with 10% FCII (ThermoScientific, Waltham, 
USA), 1% Penicillin-Streptomycin (PS, Life Technologies, Carlsbad, USA). PC-3M-
Pro4Luc2 and PC-3M-Pro4Luc2dTomato cells were cultured in the same medium 
supplemented with 0.8 mg/ml Neomycin (Santacruz, Dallas, USA) or Neomycin and 1 
µg/ml Blasticidin (Sigma-Aldrich, Zwijndrecht, The Netherlands) respectively. C4-2B 
cells were cultured in T-medium DMEM (Sigma-Aldrich, St. Louis, Missouri, USA) 
supplemented with 20% F-12K nutrient mixture Kaighn’s modification (GibcoBRL, 
Waltham, Massachusetts, USA), 10% FCS, 0.125 mg/ml biotin, 1% Insulin-
Transferrin-Selenium (ITS), 6.825 ng/ml T3, 12.5 mg/ml adenine, 1% PS. The 
dTomato clones were supplemented with 1 µg/ml Blasticidin. Osteoblasts were 
derived and differentiated as we previously described (17). Culture was maintained in 
DMEM supplemented with 1% PS and 1% ITS. All cells were maintained at 37 oC 
and 5% CO2. 
 
Knockdown of MCAM with shRNA transfection 
Short hairpin RNA (shRNA) constructs were obtained from Sigma’s MISSION library 
(MCAM clone# TCRN0000151337 (shRNA#1), TCRN0000155692 (shRNA#2), 
TCRN0000154854 (shRNA#3)). As a negative control, scrambled shRNA (SHC002, 
pLKO.1, shRNA-NT) with a lack of homology with any mammalian mRNA sequence 
was used.  
 
RNA isolation and RT-qPCR 
Total RNA was extracted using Trizol (Invitrogen, Waltham, USA) and cDNA 
synthesized by reverse transcription according to manufacturer’s instructions 
(Promega, Madison, USA). Real-time qPCR was performed with QuantStudio3 
system (Thermofisher, Waltham, MA). ACTIN, HPRT and GAPDH housekeeping 
genes were included for normalization. Primer sequences are reported in Suppl. 
Table 1. Data are displayed as 2^-DCt when Relative Expression is indicated on the 
“Y” axes. 
 
Western Blot 
Anti-vimentin (Ab8979, Abcam, MA, USA) was diluted 1:1000; anti-e-cadherin was 
diluted 1:1000 (AF648, R&D, Minneapolis, MN, USA); anti-cripto was diluted 1:1000 
(clone no. PBL6900 (17)). Detection was performed with 1:10000 secondary 
horseradish peroxidase (hrp) antibody (NA931VS, NA934VS, Sigma-Aldrich, St. 
Louis, MO, USA). Actin was detected with 1:20000 hrp antibody (A3854, Sigma-
Aldrich). 
 
Flow cytometry, ALDEFLUOR and viable cell sorting 
Functional MCAM protein expression was determined by fluorescence-activated cell 
sorting (FACS) with mouse IgG1 anti-human MCAM-Alexa647 clone P1H12 (BD 
Biosciences. Franklin Lakes, NJ, USA). Nonspecific binding was excluded by staining 
with an isotype control antibody (mouse IgG1, BD Biosciences, Franklin Lakes, NJ, 
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USA). ALDH activity of the tumour cells was measured by the ALDEFLUOR assay kit 
(StemCell Technologies, Durham, USA) according to the manufacturer’s instructions 
(17). Gating is obtained by acquisition of a control tube for each sample. Therefore, 
the percentage of ALDHhigh cells in the control gate correspond always to 0.01% of 
total. Subsequently the same gate is applied to the sample to assess the percentage 
of ALDHhigh cells in each experimental condition. After sorting, samples were 
controlled to assess purity of the sorted cell populations. 
 
Proliferation assay 
Cells were seeded at a density of 1500 cells per well and growth monitored for 24h, 
48h, 72h or 96h. For each time point, AU 490nm was measured 2h after incubation 
with 20 µl of 3-(4,5 dimethylthiazol- 2-yl)- 5 -(3 -carboxymethoxyphenyl)- 2 -(4 -
sulfophenyl)- 2 Htetrazolium (MTS - Promega, Madison, Wisconsin, United States) at 
37oC according to manufacturer’s protocol. Data were normalized for the number of 
cells seeded. N=5 per condition, performed at least in biological triplicates. 
 
Animal experiments 
CB17 SCID male mice, 5-6 weeks old were intra-osseous (IO) injected with 50.000 
PC-3M-Pro4Luc2dTomato cells bearing the stable shRNA#1 to knockdown MCAM 
expression or non-targeted (NT) shRNA control sequence. Sham operated mice were 
included as additional control (data not shown). Body weight measure, BLI imaging 
(NightOwl, Berthold, Bad Wildbad, Germany) and x-ray assessment (Faxitron 
Bioptics, Tucson, Arizona, US), were conducted to monitor the healthy status of the 
animals, the growth of the tumor cells and the progression of the lesions respectively. 
Bone morphometry was conducted as described by Bassett et al. (20). A dose of 
anti-MCAM monoclonal antibody (mAb) 10mg/kg was used (for both the rat anti-
mouse and rat anti-human molecule) and animals injected intraperitoneally (i.p.). 
Same dose was applied to the control IgG molecules. Monoclonal rat IgG1 anti-
human MCAM (clone 2107) and rat anti-mouse MCAM mAb (clone 15) were kindly 
provided by Prothena Biosciences (South San Francisco Ca, USA) (21,22). The anti-
human MCAM antibody has previously been tested in 2 clinical trials 
(ClinicalTrials.gov Identifier: NCT02630901 and NCT02458677). Control IgG (rat Fc 
and human Fc) were purchased from BioXCell (BE0096 and BE0094, West Lebanon, 
NH, USA). For zebrafish experiment, Tg(fli1:GFP)i114 zebrafish line (23) was 
handled according to local animal welfare regulations to standard protocols 
(http://www.ZFIN.org). Two days postfertilization, dechorionized zebrafish embryos 
were anesthetized and injected with PC-3M-Pro4Luc2dTomato cells as described 
previously (17). Data are representative of at least two independent and blind 
experiments with ⩾30 embryos per group. Survival rate of control group lower than 
80% was used as discard cut-off. Images were acquired with Leica SP8 confocal 
(Leica, Germany).  
 
RNA sequencing  
A biological triplicate for MCAM knockdown cells (shRNA#1) and control samples 
(shRNA-NT) of the cell line employed for the in vivo study was generated and total 
RNA extracted using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). Samples 
were measured with NextSeq500 (Illumina, San Diego, US). Image analysis, base 
calling, and quality check was performed with the Illumina data analysis pipeline RTA 
v2.4.11 and Bcl2fastq v2.17. Sequence reads were aligned using STAR two-pass 
(24) to the human reference genome GRCh37 and gene counts quantified using the 
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‘GeneCounts’ option. Per-gene counts-per-million (CPM) were computed and log2-
transformed adding a pseudo-count of 1 to avoid transforming 0. Genes with log2-
CPM <1 in more than 3 samples were removed. Unsupervised clustering was 
performed using the top 500 most variable genes, Euclidean distance as the distance 
metric and the Ward clustering algorithm, using the ConsensusClusterPlus (25) R 
package. Differential expression analysis between MCAM knockdown cells and 
control samples was performed using the edgeR (26) R package. Normalization was 
performed using the “TMM” (weighted trimmed mean) method and differential 
expression was assessed using the quasi-likelihood F-test. Genes with false 
discovery rate (FDR)<0.05 were considered differentially expressed. Genes 
differentially expressed by >2-fold were reported. Gene Set Enrichment Analysis 
(GSEA) was performed using the Preranked tool(27) for the, C2 (canonical 
pathways) and C5 (biological processes)(28). Genes were ranked based on the F-
statistic from the differential expression analysis, multiplying F-statistic of down-
regulated genes by -1. Pathways with FDR<0.25 were considered significant. As an 
alternative, pathway analysis was also performed for the set of differentially 
expressed genes using g:Profiler(29). Enrichment maps for GSEA and g:Profiler data 
were generated with Cytoscape(30). Sets of genes with p-value cut-off 0.05 were 
included and similarity coefficient of 0.5 was applied. The RNA-seq data have been 
deposited at the NCBI Sequence Read Archive under the accession SRP151808. 
 
Analysis of publicly available dataset for transcriptomic and genomic 
evaluation and for gene expression-based survival calculation 
mRNA data for MCAM expression were extracted with ShinyGEO (31) from the 
GSE6919 (32,33), GSE6752 (32) and GSE101607 (34) dataset and analyzed with R. 
Gene expression based survival analysis for MCAM was conducted with PROGgene 
(35) on GSE40272 (36). 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6.0 (San Diego, CA, USA) 
using t-test for comparison between two groups or ANOVA for comparison between 
more groups. Two-way ANOVA was used to examine the influence of knockdown 
and control cells on the dependent variable (time) in the in vivo study. Data are 
presented as mean±SEM or mean±SD. P-values ≤0.05 are considered to be 
statistical significant (*p≤0.05, **p<0.01, ***p<0.001).  
 
Study Approval 
Animal experiment was approved by the local ethical committee of Canton of Bern, 
Switzerland (Permit Number BE 55/16) and carried out in accordance with Swiss 
Guidelines for the Care and Use of Laboratory Animals. 
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Results 
 
MCAM is highly expressed in PCa and associated metastasis 
MCAM expression correlates with poor prognosis in several types of cancer, 
including PCa (37). We investigated the levels of MCAM in normal (N=18), tumor 
(N=65) and tumor adjacent tissues (N=63) and PCa metastasis (N=20) in the 
GSE6919 and GSE6752 datasets (32,33), which include transcriptional data for 
primary site and androgen-ablation resistant metastases. We found that MCAM was 
increased in tumor (p=0.056) and tumor adjacent tissue (p=0.043) compared to 
normal samples (Figure 1A and 1B). MCAM levels were similar in tumor and tumor 
adjacent tissues (Figure 1C). Moreover, MCAM was strongly increased in PCa 
metastases (N=20) compared to primary tumors (N=10) (p<0.001 Figure 1D). 
Subsequent fractionation of MCAM expression in metastases from various soft 
tissues (lymph node, adrenal, liver and lung) also revealed a significant increase in 
MCAM expression in these sites compared to the primary tumor site (p=0.001 Figure 
1E). The relation between MCAM expression and PCa recurrence in GSE40272 (36) 
suggested an involvement of high MCAM expression in disease relapse, although 
this did not reach significance (Suppl. Figure 1A and 1B). 
Previously, it was demonstrated that a subpopulation of ALDHhigh cells isolated from 
the aggressive PC-3M-Pro4 PCa cell line displays high clonogenicity in vitro and 
possesses the ability to generate bone metastases in preclinical mouse models, 
compared to non-tumorigenic non-metastatic ALDHlow (38). Therefore, we measured 
the expression of MCAM in selected subpopulations of human PCa cells from the 
PC-3M-Pro4 cell line and tested whether it was possible to identify a subset of 
MCAMhigh cells with aggressive features. Using viable cell sorting, we identified 4 
subsets of cells: ALDHhighMCAMhigh; ALDHhighMCAMlow; ALDHlowMCAMhigh; and 
ALDHlowMCAMlow (Figure 1F and Suppl. Figure 1C). Analysis of MCAM expression 
by quantitative real-time PCR (RT-qPCR) confirmed that we successfully isolated a 
subset of MCAMhigh cells by flow cytometry (Figure 1G). However, when tested for 
colony forming capacity, the 4 subpopulations of cells displayed similar behavior 
(Figure 1H and I). 
 
Characterization of MCAM knockdown cell lines and extravasation ability 
We studied the functional role of MCAM in AR-negative and lytic-PCa PC-3M-Pro4 
and PC-3M-Pro4 luc2dTomato cells, and in AR-positive and blastic- C4-2B and C4-
2BdTomato cells (17).  
To investigate the function of MCAM, we used lentiviral delivery of three independent 
MCAM-targeting shRNAs (MCAM KD) and one control non-targeting shRNA (NT). 
RT-qPCR showed significant reduction of MCAM mRNA with each of the 3 MCAM 
shRNAs (shRNA#1; shRNA#2; shRNA#3) compared to the non-targeted control 
(shRNA-NT) (Suppl. Figure 2A). Measurement of functionally active protein by flow 
cytometry showed marked reduction of MCAM levels with shRNA#1 (approximately 
30% reduction vs. NT control cells), whereas similar protein levels were measured for 
shRNA#2 and shRNA#3 (Figure 2A). In C4-2B cells, RT-qPCR displayed strong 
reduction of MCAM mRNA by each of the 3 shRNAs compared to NT control (Suppl. 
Figure 2B). Analysis of functionally active protein expression by flow cytometry 
showed higher reduction with shRNA#1 and shRNA#3 vs. NT control, compared to 
shRNA#2 (Figure 2B), in line with the transcriptional data. 
We found that MCAM knockdown caused a reduction in cell proliferation in vitro in 
PC-3M-Pro4 cells (p<0.01 for shRNA#1 and shRNA#3 at 72 hours and p<0.001 for 
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shRNA#1 at 96 hours with Bonferroni’s multiple comparison test, compared to NT 
control Figure 2C). Similarly, in C4-2B cells, MCAM knockdown reduced proliferation 
in vitro (p<0.001 for shRNA#1, shRNA#2 and shRNA#3 at 72 hours and p<0.001 for 
shRNA#3 at 96 hours with Bonferroni’s multiple comparison test Figure 2D). Based 
on these results and on the knockdown validation at the protein level, we selected the 
shRNA#1 to continue with subsequent in vitro and in vivo characterization. 
To assess the role of MCAM in the modulation of ALDH activity in PC-3M-Pro4 cells 
we employed the ALDEFLUOR assay (Figure 2E). MCAM knockdown cells 
displayed a lower percentage of ALDHhigh cells compared to NT control, although this 
did not reach statistical significance (Figure 2F). Similarly, no change was observed 
in C4-2B PCa cells (Figures 2G and 2H). This suggests that knockdown of MCAM 
does not cause depletion of the ALDHhigh population of human PCa cells. Analysis of 
a panel of EMT markers (E-Cad, N-Cad, Vim, Zeb1, Zeb2, Snail1, Snail2 and Twist) 
in the presence or absence of MCAM knockdown suggests that suppressing MCAM 
expression promotes an epithelial transcriptional phenotype as shown by the 
significant increase in the ratio E-Cad/Vim in both cell lines (p<0.001 for PC-3M-Pro4 
and p<0.01 for C4-2B Figure 3A and 3B) and by the increase in the ratio E-Cad/N-
Cad in PC-3M-Pro4 (p<0.001 Suppl. Figure 2C-D-E). However, evaluation of protein 
expression by western blot revealed a non-significant alteration in E-Cadherin and 
Vimentin expression (Figure 3C-D-E and 3F– left panel) and in the ratio E-Cad/Vim 
(Figure 3F – right panel). We used zebrafish to assess the impact of MCAM 
knockdown on the ability of PCa cells to extravasate, which is an EMT feature, and to 
grow at distant sites (Suppl. Figure 2F). Quantification of disseminated cells at 1 day 
post injection (dpi) and 4 dpi revealed similar behavior in knockdown and control 
(Suppl. Figure 2G), supporting our analysis on E-Cadherin and Vimentin expression. 
 
MCAM is required for osteoblast-mediated induction of ALDH activity in PCa 
cells and is increased upon castration 
The osteoblastic microenvironment in bone functions as premetastatic niche by 
attracting bone-metastasizing PCa cells (5). We have previously shown that co-
culture of human PCa cells and mature human osteoblasts leads to increase in the 
percentage of highly metastatic ALDHhigh PCa cells (17). 
To investigate the role of MCAM in the context of the osteoblastic niche, we 
performed direct co-culture of MCAM knockdown PCa cells and human osteoblasts. 
After 48 hours of co-culture, the dTomato labelled PC-3M-Pro4 PCa cells were 
separated from the osteoblasts by viable cell sorting (Figure 3G). Immediately after 
sorting, we measured the ALDH activity of the sorted PC-3M-Pro4 MCAM knockdown 
(ShRNA#1) and control PCa cells (Sh-NT) that were either co-cultured (Sh-NT+OB; 
ShRNA#1+OB Figure 3H. Each condition includes its own gating control, small insert 
in each panel) or not co-cultured (Sh-NT-OB; ShRNA#1-OB Figure 3H) with 
osteoblasts. In the absence of osteoblast co-culture, NT and MCAM knockdown cells 
each displayed similar percentages of ALDHhigh cells (Figure 3I – CTRL bars). 
However, when co-cultured with osteoblasts, the MCAM knockdown PCa cells 
displayed a significant reduction in the percentage of ALDHhigh cells - when compared 
to NT PCa cells co-cultured with osteoblasts (p<0.01 Figure 3I – OB bars). This 
result indicates that MCAM plays a role in maintaining levels of ALDH activity in PCa 
cells in the presence of osteoblast cells in co-culture and suggests that it may play a 
similar role within the osteoblastic microenvironment. To test if there is cross-talk 
between MCAM and the androgen signaling in the context of PCa bone metastasis, 
we evaluated the expression level of MCAM and its extracellular matrix interaction 
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partner laminin alpha 4 (LAMA4) in the GSE101607 dataset (34), which contains 
fresh-frozen bone metastasis samples from AR driven (N = 32) and non-AR driven (N 
= 8) tumors. We found a significant increase in MCAM (p=0.044) and LAMA4 
(p=0.045) in non-AR-driven conditions compared to AR-driven (Figure 4A and 4B). 
This reinforces the hypothesis that MCAM levels increase upon disease progression. 
Furthermore, we evaluated the effect of DHT administration in C4-2B cells under 
high-castration conditions in Charcoal Stripped Medium for 72 hours (39) (Figure 
4C). The androgen response was compared in control and MCAM knockdown cells 
by evaluating the expression of 4 androgen responsive genes upon DHT stimulation 
(10nM) (40). C4-2B cells displayed an intact AR machinery as indicated by the strong 
upregulation of FKBP5, KLK3 and TMPRSS2 and by the downregulation of OPRK1 
(Figure 4D) (40). No difference was detected between control and knockdown cells, 
indicating that MCAM has no influence on the androgen responsiveness in C4-2B 
cells. Similarly, administration of the anti-androgen MDV3100 (Enzalutamide) 
revealed no difference in the modulation of the AR responsive genes in control and 
knockdown cells (Figure 4E). Interestingly, we observed a consistent downregulation 
of OPRK1 in MCAM knockdown cells compared to control. Finally, while no change 
was observed on MCAM expression upon MDV3100 treatment compared to DMSO 
control, DHT administration resulted in a strong reduction of MCAM expression 
compared to castration (EtOH control in Charcoal Stripped Medium) (Figure 4F). 
This supports our dataset analysis and indicates that MCAM levels are higher upon 
castration. 
  
MCAM knockdown reduces PCa lytic bone metastasis in a preclinical mouse 
model  
To test the impact of MCAM knockdown on bone metastasis of PCa cells, we 
performed intra-osseous (IO) inoculation of PC-3M-Pro4 MCAM knockdown cells and 
NT control cells expressing Luciferase2 (Luc2) in male mice (sham-operated mice 
were included as an additional control). Animals were monitored by bioluminescent 
imaging (BLI) during the course of the experiment (4 weeks, Figure 5A. All animals, 
at day 7 and day 28 displayed in Suppl. Figure 3A). Luciferase activity of MCAM 
knockdown and NT control cells was assessed by serial cell dilution to confirm that 
there was no external influence of the shRNAs employed on BLI signal detection 
(Suppl. Figure 3B). Body weight of the animals was monitored along the course of 
the experiment (Suppl. Figure 3C) and the development of bone lesions was 
assessed by X-Ray measurements (Figure 5B. Data for all mice, including sham, at 
day 7 and day 28 are displayed in Suppl. Figure 3D). We found that MCAM 
knockdown strongly reduced the lytic-phenotype of PC-3M-Pro4 cells compared to 
NT control. This was confirmed by bone morphometric analysis (Figure 5C and 
Suppl. Figure 3E, analysis at day 28) and histological evaluation (Figure 5D and 
Suppl. Figure 3F). Bone morphometry revealed that bone area in knockdown was 
similar to sham and significantly higher in mice injected with MCAM knockdown cells 
compared with those injected with NT control cells (p<0.05 Figure 5E) despite the 
fact that BLI measurement revealed similar tumor burden between MCAM 
knockdown and NT control cells (Figure 5F). Finally, we used RT-qPCR to measure 
the expression of a panel of genes previously identified as regulators of multiple 
steps of the bone metastatic cascade (TDGF1/CRIPTO, PMEPA1, COL1a, VEGFa, 
DKK1, PTHLH, MSF) (17,41). We found a strong inhibition of the oncogene 
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CRIPTO/TDGF1 (42) in MCAM knockdown cells compared to NT control (p<0.05) 
and a general modulation of molecules involved in bone remodeling (e.g. PTHLH and 
DKK1 Figure 5G). The downmodulation of CRIPTO/TDGF1 in MCAM knockdown 
cells was confirmed also at protein level (Figure 5H). Taken together, our data 
suggest that MCAM influences the expression of molecules that are important 
modulators of bone remodeling and bone metastasis. 
 
MCAM knockdown impacts expression of genes that regulate hematopoiesis 
and bone remodeling  
To identify the putative mechanisms of action of MCAM, we performed RNA-
sequencing on MCAM knockdown cells. Unsupervised hierarchical clustering 
demonstrated a separation between MCAM knockdown and control NT samples 
(Figure 6A, heatmap and volcano plot in upper and lower panel, respectively). 
Differential expression analysis between MCAM knockdown and NT control revealed 
that 55 different genes were significantly upregulated (> 2 fold increase, FDR < 0.05) 
and 99 significantly downregulated (> 2 fold decrease, FDR < 0.05) (Suppl. Table II 
and Suppl. Table III). We performed gene set enrichment analysis (GSEA)(27) to 
identify biological processes and pathways modulated by MCAM knockdown (Figure 
6B). We found that the upregulated genes in MCAM knockdown cells were enriched 
for the process related to negative regulation of hematopoiesis (normalized 
enrichment score (NES)=1.68, p=0.02, Figures 6C and Suppl. Table IV for the list of 
14 genes involved in the pathway). This supports our previous findings (6) and the 
notion that increasing the number of HSC niches increases metastatic growth in the 
bone marrow (5). Additionally, we found an enrichment of GO processes of 
biomineral tissue development (NES=1.8, p=0.002) and bone mineralization 
(NES=1.68, p=0.008) among the genes upregulated upon MCAM knockdown 
(Figures 6D, 6E and 6F). This support the hypothesis that MCAM knockdown 
disrupts signaling pathways associated to bone remodeling and are in accordance 
with our in vivo experiment. 
Among the genes downregulated in MCAM knockdown cells, we found an 
enrichment of genes involved in G0 and early G1 (NES = -1.5, p=0.02) and in E2F 
mediated regulation of DNA replication (NES = -1.5, p=0.01) (Suppl. Figure 4A and 
B and Suppl. Table V and VI). These data reinforce our finding that MCAM 
knockdown cells displayed reduced proliferation in vitro. Similar results were obtained 
using an alternative gene set analysis method g:Profiler (Suppl. Figures 4C and D). 
 
Targeting MCAM with a monoclonal antibody reduces intra-osseous growth 
and diminishes the extension of lytic-lesions in an intra-osseous model 
To test the effect of targeting MCAM on both the tumor and the stroma in a preclinical 
intra-osseous model of PCa bone metastasis, we employed an anti-human and anti-
mouse MCAM mAb. Five animals per experimental group (anti-human, anti-mouse, 
anti-human+mouse, control IgG rat, control IgG human) were pre-treated with 
10mg/kg of mAbs and controls IgG intraperitoneally the day prior to intra-bone injec-
tion of PCa cells. After intra-bone injection, all animals received administration of the 
mAbs or controls IgG every second day at a dose of 10mg/kg intraperitoneally. Ani-
mals were monitored by BLI during the course of the experiment (5 weeks, Figure 
7A, all animals at end of experiment displayed in Suppl. Figure 5A). Administration 
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of anti-human MCAM mAb resulted in significantly smaller intra-osseous growth 
(p<0.05 Figure 7B). Body weight was evaluated, and development of bone lesions 
was monitored during the experiment with x-ray (Figure 7C and 7D, all animals dis-
played in Suppl. Figure 5B and statistic in Suppl. Figure 5C). Additionally, lucifer-
ase activity of PCa cells was evaluated prior to in vivo experimentation (Suppl. Fig-
ure 5D). Bone morphometric analysis and histological evaluation revealed a higher 
bone area in animals treated with anti-human mAbs compared to other experimental 
groups (p<0.05, Figure 7E and 7F, all animals displayed in Suppl. Figure 6A-D. Sta-
tistical evaluation displayed in Suppl. Figure 6B and C). Evaluation of the kidney 
histology revealed normal and comparable histological characteristics in all the ex-
perimental groups (Suppl. Figure 7A). Contralateral bones as control of normal his-
tological features were collected and displayed in Suppl. Figure 7B.  
 
Discussion 
In this study we provide evidence that MCAM drives lytic-metastatic human PCa and 
has potential as a therapeutic target in metastatic PCa.  
Our in vivo experiments revealed that MCAM knockdown in PCa cells reduces their 
ability to generate lytic lesions upon inoculation into the bone. We found that MCAM 
knockdown cells and NT control cells displayed similar tumor burden in vivo despite 
showing different cell proliferation rates in vitro. This supports the notion that, in the 
presence of the bone microenvironment, MCAM has a prominent role in modulating 
the process of bone remodeling and suggests that, in this context, other mechanisms 
sustain the proliferation of tumor cells. Treatment with an anti-MCAM mAb revealed 
significant impact on lytic-lesions in the mice bearing PCa cells in the bone. This 
finding is in line with the results of our in vivo experiment with MCAM knockdown. 
However, administration of anti-MCAM mAb also resulted in lower tumor burden in 
the intra-osseous model. This might be related to the residual level of MCAM in our 
knockdown line (approximately 30% knockdown on the protein level) compared to the 
administered mAb. We showed here that the reduction in MCAM expression is 
sufficient to influence the expression of the oncogenic driver CRIPTO/TDGF1 (43). 
This suggests that in MCAM knockdown in PCa cells, the proliferation in vitro might 
be supported by TDGF1. Consistent with this possibility, we have previously shown 
that TDGF1 knockdown decreases cell proliferation in vitro and bone metastases in 
vivo and that TDGF1 mRNA increases upon direct co-culture of human PCa cells 
with human osteoblasts (17). While MCAM knockdown does not prevent PCa growth 
in bone, it does impact on the lytic-phenotype. This role of MCAM is supported by our 
RNA sequencing data and transcriptional analysis on a set of genes that was 
previously shown to regulate bone metastasis in lytic-PCa cells (41). MCAM 
knockdown reduces the mRNA of the osteolytic-factor PTHLH (44) and the Wnt 
inhibitor dickkopf-1 (DKK-1) (45). DKK-1 expression was proposed as an early event 
in skeletal metastasis thus favouring osteolysis at the metastatic site (45). 
Additionally, the concurrent downregulation of PTHLH upon MCAM knockdown might 
explain the effect on cell proliferation measured in vitro, given that PTHLH was 
shown to play a role in PCa cells proliferation (46). 
We found that in human PCa patients MCAM is significantly elevated in androgen-
ablation resistant metastases relative to primary tumors. This is in line with our 
findings that MCAM is elevated upon castration. Moreover, this matches previous 
clinical literature reporting that MCAM expression is strongly related to poor 
prognosis in a variety of carcinomas including prostate cancer (37).  
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We have shown that while it is possible to isolate a fraction of MCAMhigh and 
MCAMlow cells, their molecular features do not necessarily overlap with those of 
“bulk” ALDHhigh and ALDHlow cells as shown by our clonogenic assay. This suggests 
that further subpopulations of cells might display independent phenotypic 
characteristics as we showed here for the MCAMhigh fraction.  
Our findings also suggest that the modulation of MCAM expression might impact on 
the transcriptional program of EMT related genes. This is in line with previous studies 
showing that MCAM promotes EMT and EMT-related drug resistance (47). However, 
our data on protein expression highlight a lack of significant effect on the detection of 
E-cadherin and vimentin at the protein level, possibly due to residual MCAM protein. 
Extravasation is one of the feature of EMT and MCAM knockdown PCa cells 
behaved similarly to control cells when injected into zebrafish. Treatment with DHT 
and MDV3100 revealed no difference in the response of control and knockdown cells 
to androgen stimulation or blockade. However, administration of DHT resulted in a 
strong decrease in MCAM expression compared to castration. This finding and our 
analysis of two PCa bone metastasis subset of AR driven and non-AR driven 
disease, supports the involvement of MCAM during disease progression and 
reinforce the hypothesis of targeting MCAM in advanced disease.  
In conclusion, we have analysed the role of MCAM in PCa cells by investigating its 
biological function with models that recapitulate the presence and absence of 
androgens and the ostoblastic-niche in vitro and the context of the bone 
microenvironment in vivo. Although additional studies are required to dissect the 
molecular function of MCAM, our data indicate that MCAM is required for producing 
the lytic-phenotype in PCa bone metastasis. Moreover, we showed here that 
treatment with anti-MCAM monoclonal antibody has a significant impact on PCa cells 
growth intra-bone and diminishes the extension of lytic lesions. Our findings affirm 
the potential utility of MCAM targeting agents that are able to interfere with its 
biological function for use in treating metastatic disease to the bone. The combination 
of these agents with currently available drugs that target PCa growth might lead to 
better treatment for PCa patients, especially those with life-threatening metastatic 
disease.  
 
Author contributions 
EZ, LA, GvdP, GNT and MK designed the study. EZ and LA performed the 
experiments, analysed the data and wrote the manuscript. JM, JG, LC and IK 
performed the experiments. PK, KF and ES provided reagents. CKY and SP 
analysed the RNA sequencing data and helped with the writing of the paper. 
 
Acknowledgements 
The authors thank Guido de Roo and Sabrina Veld from the flow cytometry facility 
(Department of Hematology, LUMC, The Netherlands). We also would like to thank 
Stefan Müller, Bernadette Nyfeler and Thomas Schaffer from the FACS laboratory 
(Department of BioMedical Research, UniBern, Switzerland). Monoclonal anti-human 
MCAM and rat anti-mouse MCAM antibodies were kindly provided by Prothena 
Biosciences.  
 
 
 
 
Research. 
on February 25, 2019. © 2019 American Association for Cancermcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 11, 2019; DOI: 10.1158/1541-7786.MCR-18-1220 
Page 12 of 19 
 
 
 
 
 
References 
 
1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer 
incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 
2010;19(8):1893-907 doi 10.1158/1055-9965.EPI-10-0437. 
2. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et 
al. External irradiation with or without long-term androgen suppression for 
prostate cancer with high metastatic risk: 10-year results of an EORTC 
randomised study. Lancet Oncol 2010;11(11):1066-73 doi 10.1016/S1470-
2045(10)70223-0. 
3. La Manna F, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN, 
et al. Metastases in Prostate Cancer. Cold Spring Harb Perspect Med 2018 
doi 10.1101/cshperspect.a033688. 
4. Hensel J, Thalmann GN. Biology of Bone Metastases in Prostate Cancer. 
Urology 2016;92:6-13 doi 10.1016/j.urology.2015.12.039. 
5. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. 
Human prostate cancer metastases target the hematopoietic stem cell niche to 
establish footholds in mouse bone marrow. J Clin Invest 2011;121(4):1298-
312 doi 10.1172/JCI43414. 
6. Özdemir BC, Hensel J, Secondini C, Wetterwald A, Schwaninger R, 
Fleischmann A, et al. The Molecular Signature of the Stroma Response in 
Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion 
of Hematopoietic and Prostate Epithelial Stem Cell Niches. PLoS ONE 
2014;9(12):e114530 doi 10.1371/journal.pone.0114530. 
7. Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP. Genomic 
organization of the melanoma-associated glycoprotein MUC18: implications 
for the evolution of the immunoglobulin domains. Proceedings of the National 
Academy of Sciences 1993;90(18):8514-8 doi 10.1073/pnas.90.18.8514. 
8. Wu G-J, Wu M-WH, Wang S-W, Liu Z, Qu P, Peng Q, et al. Isolation and 
characterization of the major form of human MUC18 cDNA gene and 
correlation of MUC18 over-expression in prostate cancer cell lines and tissues 
with malignant progression. Gene 2001;279(1):17-31 doi 10.1016/s0378-
1119(01)00736-3. 
9. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, et al. Expression 
of MCAM/MUC18 by human melanoma cells leads to increased tumor growth 
and metastasis. Cancer Res 1997;57(11):2295-303. 
10. Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of 
the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer. 
Analytical Cellular Pathology 2003;25(2):77-81 doi 10.1155/2003/574829. 
11. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et 
al. M-CAM expression as marker of poor prognosis in epithelial ovarian 
cancer. International Journal of Cancer 2006;119(8):1920-6 doi 
10.1002/ijc.22082. 
12. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. 
CD146 expression is associated with a poor prognosis in human breast 
Research. 
on February 25, 2019. © 2019 American Association for Cancermcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 11, 2019; DOI: 10.1158/1541-7786.MCR-18-1220 
Page 13 of 19 
 
tumors and with enhanced motility in breast cancer cell lines. Breast Cancer 
Res 2009;11(1):R1 doi 10.1186/bcr2215. 
13. Wu G-J, Wu M-WH, Wang C, Liu Y. Enforced Expression of METCAM/MUC18 
Increases Tumorigenesis of Human Prostate Cancer LNCaP Cells in Nude 
Mice. The Journal of Urology 2011;185(4):1504-12 doi 
10.1016/j.juro.2010.11.052. 
14. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-
mesenchymal transition inducer, is associated with triple-negative breast 
cancer. Proceedings of the National Academy of Sciences 2011;109(4):1127-
32 doi 10.1073/pnas.1111053108. 
15. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, et al. 
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a 
hematopoietic microenvironment. Cell 2007;131(2):324-36 doi 
10.1016/j.cell.2007.08.025. 
16. Bardin N. Identification of CD146 as a component of the endothelial junction 
involved in the control of cell-cell cohesion. Blood 2001;98(13):3677-84 doi 
10.1182/blood.v98.13.3677. 
17. Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, et al. 
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in 
human osteotropic prostate cancer. Oncogene 2017;36(33):4739-49 doi 
10.1038/onc.2017.87. 
18. Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, Pelger RC, et 
al. miR-25 Modulates Invasiveness and Dissemination of Human Prostate 
Cancer Cells via Regulation of alphav- and alpha6-Integrin Expression. 
Cancer Res 2015;75(11):2326-36 doi 10.1158/0008-5472.CAN-14-2155. 
19. Kroon J, in 't Veld LS, Buijs JT, Cheung H, van der Horst G, van der Pluijm G. 
Glycogen synthase kinase-3&beta; inhibition depletes the population of 
prostate cancer stem/progenitor-like cells and attenuates metastatic growth. 
Oncotarget 2013;5(19):8986-94 doi 10.18632/oncotarget.1510. 
20. Bassett JH, van der Spek A, Gogakos A, Williams GR. Quantitative X-ray 
imaging of rodent bone by Faxitron. Methods Mol Biol 2012;816:499-506 doi 
10.1007/978-1-61779-415-5_29. 
21. Breuer J, Korpos E, Hannocks MJ, Schneider-Hohendorf T, Song J, Zondler L, 
et al. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the 
choroid plexus. J Neuroinflammation 2018;15(1):236 doi 10.1186/s12974-018-
1276-4. 
22. Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, et al. 
Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into 
the CNS. PLoS One 2012;7(7):e40443 doi 10.1371/journal.pone.0040443. 
23. Stoletov K, Montel V, Lester RD, Gonias SL, Klemke R. High-resolution 
imaging of the dynamic tumor cell vascular interface in transparent zebrafish. 
Proc Natl Acad Sci U S A 2007;104(44):17406-11 doi 
10.1073/pnas.0703446104. 
24. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: 
ultrafast universal RNA-seq aligner. Bioinformatics 2013;29(1):15-21 doi 
10.1093/bioinformatics/bts635. 
25. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with 
confidence assessments and item tracking. Bioinformatics 2010;26(12):1572-3 
doi 10.1093/bioinformatics/btq170. 
Research. 
on February 25, 2019. © 2019 American Association for Cancermcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 11, 2019; DOI: 10.1158/1541-7786.MCR-18-1220 
Page 14 of 19 
 
26. Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq 
analysis: an application to stem cell biology. Methods Mol Biol 2014;1150:45-
79 doi 10.1007/978-1-4939-0512-6_3. 
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, 
et al. Gene set enrichment analysis: a knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 
2005;102(43):15545-50 doi 10.1073/pnas.0506580102. 
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, 
Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 
2011;27(12):1739-40 doi 10.1093/bioinformatics/btr260. 
29. Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. 
g:Profiler-a web server for functional interpretation of gene lists (2016 update). 
Nucleic Acids Res 2016;44(W1):W83-9 doi 10.1093/nar/gkw199. 
30. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. 
Cytoscape: a software environment for integrated models of biomolecular 
interaction networks. Genome Res 2003;13(11):2498-504 doi 
10.1101/gr.1239303. 
31. Dumas J, Gargano MA, Dancik GM. shinyGEO: a web-based application for 
analyzing gene expression omnibus datasets. Bioinformatics 
2016;32(23):3679-81 doi 10.1093/bioinformatics/btw519. 
32. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. 
Gene expression profiles of prostate cancer reveal involvement of multiple 
molecular pathways in the metastatic process. BMC Cancer 2007;7:64 doi 
10.1186/1471-2407-7-64. 
33. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression 
alterations in prostate cancer predicting tumor aggression and preceding 
development of malignancy. J Clin Oncol 2004;22(14):2790-9 doi 
10.1200/JCO.2004.05.158. 
34. Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, et al. 
Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined 
Through an Inverse Relationship Between Androgen Receptor Activity and 
Immune Response. Eur Urol 2017;71(5):776-87 doi 
10.1016/j.eururo.2016.07.033. 
35. Goswami CP, Nakshatri H. PROGgene: gene expression based survival 
analysis web application for multiple cancers. J Clin Bioinforma 2013;3(1):22 
doi 10.1186/2043-9113-3-22. 
36. Gulzar ZG, McKenney JK, Brooks JD. Increased expression of NuSAP in 
recurrent prostate cancer is mediated by E2F1. Oncogene 2013;32(1):70-7 doi 
10.1038/onc.2012.27. 
37. Wu G-J, Varma VA, Wu M-WH, Wang S-W, Qu P, Yang H, et al. Expression 
of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and 
tissues. The Prostate 2001;48(4):305-15 doi 10.1002/pros.1111. 
38. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-
Ramirez N, et al. High Aldehyde Dehydrogenase Activity Identifies Tumor-
Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer 
Research 2010;70(12):5163-73 doi 10.1158/0008-5472.can-09-3806. 
39. Sedelaar JP, Isaacs JT. Tissue culture media supplemented with 10% fetal 
calf serum contains a castrate level of testosterone. Prostate 
2009;69(16):1724-9 doi 10.1002/pros.21028. 
Research. 
on February 25, 2019. © 2019 American Association for Cancermcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 11, 2019; DOI: 10.1158/1541-7786.MCR-18-1220 
Page 15 of 19 
 
40. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor 
gene expression in prostate cancer is directly suppressed by the androgen 
receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 
2011;20(4):457-71 doi 10.1016/j.ccr.2011.09.001. 
41. Fournier PG, Juarez P, Jiang G, Clines GA, Niewolna M, Kim HS, et al. The 
TGF-beta Signaling Regulator PMEPA1 Suppresses Prostate Cancer 
Metastases to Bone. Cancer Cell 2015;27(6):809-21 doi 
10.1016/j.ccell.2015.04.009. 
42. Klauzinska M, Castro NP, Rangel MC, Spike BT, Gray PC, Bertolette D, et al. 
The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and 
epithelial-mesenchymal transition. Semin Cancer Biol 2014;29:51-8 doi 
10.1016/j.semcancer.2014.08.003. 
43. Terry S, El-Sayed IY, Destouches D, Maille P, Nicolaiew N, Ploussard G, et al. 
CRIPTO overexpression promotes mesenchymal differentiation in prostate 
carcinoma cells through parallel regulation of AKT and FGFR activities. 
Oncotarget 2015;6(14):11994-2008 doi 10.18632/oncotarget.2740. 
44. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, et 
al. Localization of parathyroid hormone-related protein in breast cancer 
metastases: increased incidence in bone compared with other sites. Cancer 
Res 1991;51(11):3059-61. 
45. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer 
bone metastases. J Cell Biochem 2006;97(4):661-72 doi 10.1002/jcb.20735. 
46. Asadi F, Faraj M, Malakouti S, Kukreja SC. Effect of parathyroid hormone 
related protein, and dihydrotestosterone on proliferation and ornithine 
decarboxylase mRNA in human prostate cancer cell lines. Int Urol Nephrol 
2001;33(3):417-22. 
47. Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, et al. CD146 expression 
correlates with epithelial-mesenchymal transition markers and a poor 
prognosis in gastric cancer. Int J Mol Sci 2012;13(5):6399-406 doi 
10.3390/ijms13056399. 
 
  
Research. 
on February 25, 2019. © 2019 American Association for Cancermcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 11, 2019; DOI: 10.1158/1541-7786.MCR-18-1220 
Page 16 of 19 
 
Figure Legends 
 
Figure 1. High expression of MCAM is associated with PCa and PCa 
metastasis. A-C) MCAM expression in primary normal, primary PCa and tumor 
adjacent tissue (GSE6919). Expression levels are presented as boxplots. D-E) 
MCAM expression in primary PCa site compared to distant metastasis in samples 
from PCa patients (GSE6752). F) Schematic representation of viable cell sorting; a 
fraction of MCAMHigh and MCAMLow cells (approx. 20% of parental gate) is isolated 
from the ALDHHigh and from the ALDHLow subpopulation respectively. G) RT-qPCR 
on the sorted subpopulations for MCAM expression. H-I) Clonogenic assay and 
quantification of the colony forming capacity of the selected subpopulations after 
sorting. N=3 technical replicates. Data are presented as mean ± SD. . *p<0.05, 
**p<0.01; ***p<0.001. 
 
Figure 2. MCAM knockdown in PC-3M-Pro4Luc2dTomato and C4-2BdTomato 
human PCa cell lines. Functionally active protein expression is evaluated by 
flowcytometry and displayed panel (A) for PC-3M-Pro4Luc2dTomato cells and (B) for 
C4-2BdTomato. Data are represented as mean ± SD and are representative of at 
least 3 independent experiments. **p<0.01; ***p<0.001. C) Evaluation of effect of 
MCAM knockdown on cell proliferation over 96 hours in PC-3M-Pro4Luc2dTomato 
cells and control (sh-NT) cells with three independent shRNAs. Data are 
representative of at least 3 independent experiments. **p<0.01 and ***p<0.001 with 
Bonferroni Multiple Comparison test. D) Proliferation assay on C4-2BdTomato cells 
with MCAM knockdown by three independent shRNAs compared to control non-
targeted (sh-NT) cells. Data are represented as mean ± SD. ***p<0.001 with 
Bonferroni Multiple Comparison test. E) ALDEFLUOR assay on MCAM knockdown 
and non-targeted (NT) PC-3M-Pro4 cells to assess the percentage of ALDHhigh cells 
upon MCAM knockdown and (F) data quantification. Data are representative of 3 
independent experiments and represented as mean ± SD. G) ALDEFLUOR assay on 
MCAM knockdown and non-targeted (NT) C4-2BdTomato cells to assess the 
percentage of ALDHhigh cells upon MCAM knockdown and (H) data quantification. 
Data are representative of 3 independent experiments and represented as mean ± 
SD. 
 
Figure 3. Effects of MCAM knockdown on EMT markers and characterization of 
co-culture with human osteoblasts. A-B) MCAM knockdown results in increased 
ratio E-Cadherin/Vimentin and E-Cadherin/N-Cadherin. Data are representative of 3 
independent samples and normalized with housekeeping gene. Data are represented 
as mean ± SD. C-D) Western blot for E-Cadherin expression and quantification. 
Calculation is normalized to expression of actin. Data are representative of 3 
independent samples. Data are represented as mean ± SD. E-F) Western blot for 
Vimentin expression, quantification and protein ratio E-Cad/Vim. Calculation is 
normalized to expression of housekeeping (actin). Data are representative of 3 
independent samples. Data are represented as mean ± SD. G) Schematic 
representation of the co-culture experiment. PC-3M-Pro4 cells expressing dTomato 
fluorescent protein are cultured in direct contact with differentiated human 
osteoblasts for 48hrs prior to viable cells sorting. H) Representative images of FACS 
analysis on ALDH activity on PC3M-Pro4dTomato cells with non-targeted (sh-NT) 
without osteoblasts (-OB) or with osteoblasts (+OB). Assay was performed 
immediately after sorting. Same conditions are shown for the MCAM knockdown cells 
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(2 right panels, figure 3H). In each panel the small insert represents the control used 
for gating according from manufacturer’s protocol. Quantification is displayed in (I). 
Data are represented as mean ± SEM . **p<0.01 with Bonferroni Multiple 
Comparison Test.  
 
Figure 4. Expression of MCAM in non-AR driven PCa and in vitro functional 
effect of DHT treatment. A-B) MCAM and LAMA4 expression in PCa bone 
metastasis from AR driven and non-AR driven disease (in GSE101607). C) 
Schematic representation of in vitro castration and AR stimulation. N=3 technical 
replicates. D) Effect of DHT on AR responsive genes. Results are expressed as the 
mean ± SD. E) Effect of MDV3100 on AR responsive genes. F) Effect of AR 
stimulation or inhibition on MCAM expression. Results are expressed as the mean ± 
SD, * p<0.05, ** p<0.01 and *** p<0.001 with t-test. $$$ p<0.001 between EtOH 
control and DHT in the respective cell clone. 
 
Figure 5. CB17 SCID male mice inoculated with PC-3M-Pro4Luc2 human PCa 
cells with non-targeting shRNA (sh-NT) or MCAM-targeting shRNA (shRNA#1) 
or sham animals. 50.000 cells/animal. See Supplementary information for 
representation of all the single animals. A, B, C) Representative BLI images and 
bone measurements with X-Ray (B) and bone morphometric analysis (C). D) 
Representative histological analysis (H&E staining) of sections of tibia (T, Tumor; B, 
Bone; BM, Bone Marrow). E) Quantification of the bone area at day 28. Data are 
represented as mean ± SD. F) Quantification of tumor burden by BLI imaging. G) 
Expression of genes related to bone metastasis in MCAM KD and non-targeted 
control (NT) PCa cells. N=3 independent experiments, represented as ± SD. H) 
Western blot for Cripto expression. Data are representative of 3 independent protein 
isolations. 
 
Figure 6. RNA sequencing and gene set enrichment analysis. A) Heatmap illus-
trating hierarchical clustering of the samples, based on the 500 most variable genes 
and Volcano plot of -log10(p-value) against log2(fold change). Red dots are those 
with at least 2-fold difference and FDR≤0.05 (i.e. differentially expressed genes). B) 
GSEA enrichment analysis performed on C5_biological processes. Red bars = up-
regulated pathways; Blu bars = downregulated pathways. Numbers on the left (of the 
blu bars) or on the right (of the red bars) indicate the amount of genes enriched for 
each gene sets. Data are sorted for NES (x axes). C) GSEA plot for negative regula-
tors of hematopoiesis. Normalized enrichment score (NES) and p-value are indicated 
in the plot. D) GSEA enrichment plot for biomineral tissue development. E) GSEA 
enrichment plot for bone mineralization. The plots C-E illustrate profiles of the NES 
and positions of the genes on the rank ordered list in GSEA. Statistical p-value is also 
indicated. F) Enrichment map, for C5 (biological processes) displays sets of genes 
upregulated (red) or downregulated (blue) in MCAM knockdown cells. 
 
Figure 7. CB17 SCID male mice inoculated with PC-3M-Pro4Luc2 human PCa 
cells intra-bone and treated with anti-MCAM monoclonal antibody. A) 
Representative BLI images of separate experimental groups (5 animal/group, see 
supplementary material for representation of all the single animals. 50.000 
cells/animal; in the label descriptions of the group names, H = human, M = mouse) B) 
Quantification of tumor burden by BLI imaging. Data are represented as mean ± 
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SEM. C) Representative x-ray images of separate experimental groups. See 
supplementary information for representation of all the single animals. D) Body 
weight of animals measured over the course of the experiment. Data are represented 
as mean ± SD. E) Representative images of bone morphometric analysis. See 
supplementary information for representation of all the single animals and image 
processing. F) Quantification of the bone area at the end of experiment. Data are 
represented as mean ± SD. * p<0.05 with one way ANOVA and Bonferroni’s Multiple 
Comparison test. 
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